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Unrelated cord blood transplantation and 
post-transplant cyclophosphamide
The number of unrelated cord blood transplants
(UCBT) are declining in Europe,1 despite comparable out-
come with grafts using unrelated donor peripheral blood
or bone marrow.2 The reasons for the decline may be due
to the well-known slow engraftment and delayed
immune reconstitution of UCBT, which may result in a
significant risk of infections and non-relapse mortality
(NRM).3,4
Neutrophil and platelet recovery can be shortened by
direct intra-bone injection of CB cells,5 but immune
recovery remains an issue, especially when anti-thymo-
cyte globulin (ATG) is used in the conditioning regimen.5
In  the absence of  ATG, grade III-IV acute graft versus
host disease (GvHD) is reported to be 21%,6 and  when
ATG is added in the transplant platform, GvHD is
reduced (15%),6 but immune reconstitution is delayed,
leading to infectious complications, and late viral infec-
tions.4,7,8 The crucial role of ATG and the risk of over or
under exposure is further proven by the attempt to opti-
mize ATG dose based on lymphocyte counts, rather than
patient’s weight,9 and by carefully assessing the speed of
CD4 recovery according to ATG dosing pre-transplant.10
An additional reason for the decline in numbers of UCBT
is the competition of HLA haploidentical transplants
(HAPLO),11 especially performed with post-transplant
cyclophosphamide (PT-CY), as first described by the
Baltimore group.12 We have been particularly impressed
with the speed of immune recovery of HAPLO trans-
plants with PT-CY,13 with median CD4 counts on day
+100 (190/µl) comparable to CD4 counts after HLA iden-
tical sibling grafts (229/µl), and significantly higher as
compared to unrelated and cord blood grafts receiving
ATG for GvHD prophylaxis.13 
We therefore hypothesized that PT-CY would be an
effective GvHD prophylaxis regimen for patients under-
going an UCBT and, by preventing GvHD in the absence
of ATG, hematologic and immune recovery could be
accelerated, as seen in the HAPLO setting. We are now
reporting a first case.
The patient, a 42-year-old female, was diagnosed with
acute myeloid leukemia (AML) NPM1+ in December 2015
with normal cytogenetics; she was induced and achieved
a complete hematologic and NPM1 negative remission.
The patient relapsed in june 2017 and was re-induced to
a complete remission with anthracycline and cytosine
arabinoside. A 5/6 UCB unit was identified with a cell
count of 4.2x107/kg. On high resolution, the UCB unit
and the patient were mismatched at the A locus (24:03
vs. 24:02), at the B locus (18:01 vs. 38:01), and they were
DRB1 allelic matched. There was a gender mismatch (M
→F) and ABO mismatch (B+ →0+). In November 2017,
she was prepared with a conditioning regimen including
thiotepa 5 mg/kg on days -6 and -5, fludarabine 50
mg/m2 on days -4-3-2 and intravenous busulfan 3.2
mg/kg on days -4-3-2 (Figure 1). On 14.11.2017 she
received a single UCB unit. GvHD prophylaxis consisted
of intravenous cyclosporine (CsA) 3 mg/kg starting on
day 0, mycophenolate (MMF) 2 gr/day starting on day+1,
and PT-CY 30 mg/kg on days +3 and +5. CsA was
switched to oral administration on day +20.
Hematologic recovery:  the patient achieved a neu-
trophil count of 0.5x109/L on day +15 and a platelet
count of 20x109/L on day 21; platelet counts were 73 and
179 on days +50 and +100, respectively (Figure 2);
chimerism was full donor, by FISH (Y probe) and
microsatellites, from the first evaluation on day +30
(Figure 2). ABO blood group conversion was complete by
day +100. The patient was discharged on day +25, then
readmitted on day +32 for 6 days due to fever and a flu.
She has not since been readmitted to hospital. Grade I
skin GvHD developed on day +20 and was not treated. 
Immune recovery: there was a rapid increase of NK
cells up to 326/µl on day +29, followed by a decline of
NK cells and a rise in CD3+ cells. Absolute CD4 and CD8
counts on days +50, +100 and +180 were 63 and 96/µl,
92 and 98/µl, and 150 and 220/µl, respectively. Her cur-
rent counts on day +302 are CD4 885/µl, CD8 1115/µl
and NK 575/µl .The patient is alive and well, NPM1 neg-
ative 10 months post UCB.
Hematologic recovery has been a long-standing issue
of CB transplants. In a conventional CB transplant, with
or without ATG, the median neutrophil and platelet
recovery is 24 and 58 days, respectively.14 Similarly, neu-
trophil recovery is reported to occur on day 23 and 21 for
single and double CB transplants, with platelet recovery
occurring on day 58 and 85.15 Intra-bone infusion of CB
cells has been shown to accelerate platelet recovery in
one report (day 36)5 and neutrophil recovery in another
report (day 15)16: in the latter, however, platelet recovery
remains at a median of 45 days.16 Expansion of CB units
is another strategy studied to improve hematologic and
immune recovery: with the infusion of two CB units, one
of which ex vivo expanded, the neutrophil recovery is
accelerated to day 15, but platelet recovery remains at
day 33.17 The present case compares favorably with these
data with a rapid recovery of both neutrophils (day +15)
and platelets (day +21).
Immune recovery is the other crucial issue: Admiral
and coworkers have shown that the probability of T-cell
recovery (>50 CD4+ T cells/ µl within 100 days) was
decreased even in the lowest ATG exposure group after
unrelated CB transplant, while only the highest ATG
exposure group after BM/PB grafts had poor T-cell recov-
ery.18 This patient clearly met the criteria for rapid CD4
recovery (>50 CD4+ T cells/ µl within day 100), and the
lack of viral infections would confirm the strength of
immune reconstitution. However, more patients will be
needed to confirm this result. 
In conclusion, this first patient suggests that UCB
transplantation can be performed, following a myeloab-
lative conditioning regimen, with CsA, MMF and PT-CY
haematologica 2019; 104:e77
CASE REPORTS
Figure 1 Conditioning regimen and GvHD prophylaxis. T: thiotepa; B:busulfan;
F: fludarabine; CY: cyclophosphamide; MMF: mycophenolate; cyclophos-
phamide (CY) is given on day +3 and +5 (30 mg/kg) and cyclosporine is start-











for GvHD prophylaxis. Hematologic recovery as well as
immune reconstitution were both fast, with no infectious
complications, and no GvHD. A prospective trial has
been activated to assess whether this encouraging first
case can be confirmed. 
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Figure 2. Platelet recovery in this patient, duration of GvHD prophylaxis and
timing of full donor chimerism and NPM1 negativity.
